AZN Stock Recent News
AZN LATEST HEADLINES
Bloomberg Intelligence analysts identified 50 stocks for 2025, focusing on catalysts like new leadership, acquisitions, and AI advancements, with 35 paying dividends. 14 of these dividend-paying stocks meet the “safer” criteria, with free cash flow yields exceeding dividend yields, making them attractive for first-time investors. Analysts project net gains of 10% to 50.26% for the top ten Bloomberg Dividend Focus companies by March 2026, highlighting potential investment opportunities.
AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. The company is well-positioned for growth over the next few years. AstraZeneca's net debt-to-adjusted EBITDA ratio improved to just 1.5x in 2024.
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Endothelin Receptor Antagonist - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in HER2+ Metastatic Gastric Cancer.
WILMINGTON, Del.--(BUSINESS WIRE)--Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen's TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for subsequent surgery, and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared to placebo.1,2 These data were published in the New England Journal of Medicine and presented today as a late-breaking oral presentation at the American Academy of.
In the closing of the recent trading day, Astrazeneca (AZN) stood at $76.21, denoting a +0.74% change from the preceding trading day.
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for additional hormone treatments.
Dublin, Feb. 28, 2025 (GLOBE NEWSWIRE) -- The "Neurofibromatoses: Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. This reports provides a data-driven overview of the current and future competitive landscape in Nurofibromatoses therapeutics. In 2024, more than 986,000 diagnosed prevalent cases of Nurofibromatoses are anticipated in the 16 countries covered in the analyst's epidemiology forecast.
LUND, SWEDEN / ACCESS Newswire / February 27, 2025 / BioInvent International (STO:BINV) "2024 was a year with several exciting developments reported from across our broad portfolio of clinical programs. We now have two Phase 2 and four Phase 1 trials running in our six clinical programs leveraging the TNFR2 and FcyRIIB targets.
AstraZeneca PLC (LSE:AZN) has seen £2 billion added to its market value after reporting positive results from a breast cancer drug trial. The experimental treatment, camizestrant, improved patient survival without the disease worsening, according to an interim analysis.